Collaboration between SciSparc and Clearmind Medicine leads to publication of application for innovative ketamine-based combination Page 1

TEL AVIV, Israel, Aug. 29, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), a clinical-stage specialty pharmaceutical company focused on the development of therapies to treat central nervous system disorders and rare diseases, today announced that, as part of its ongoing collaboration with Clearmind Medicine Inc. (“Clearmind”) (Nasdaq: CMND) (CSE: CMND) (FSE: CWY), a biotechnology company focused on the discovery and development of novel psychedelic-based therapies to solve major undertreated mental health problems, Clearmind has announced the publication of its patent application under the international Patent Cooperation Treaty, covering novel combinations of ketamine and N-acylethanolamines.

As part of their collaboration, SciSparc and Clearmind are investigating a combination treatment consisting of SciSparc’s Palmitoylethanolamide (“PEA”) and Clearmind’s novel psychedelic molecule, MEAI, for the treatment of addiction, weight loss and mental health disorders. In addition, SciSparc and Clearmind are jointly investigating novel treatments based on psychedelic molecules and PEA. To date, thirteen patents relating to this collaboration have been filed with the US Patent and Trademark Office and several other global patent offices.